about
A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patieA novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathyPrediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA).Anderson-Fabry disease and the heart.Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease.Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease.Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy.Predictors of atrial fibrillation in hypertrophic cardiomyopathy.Rhabdomyolysis with atorvastatin and fusidic acid.Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records.Doppler echocardiography underestimates the prevalence and magnitude of mid-cavity obstruction in patients with symptomatic hypertrophic cardiomyopathy.An International External Validation Study of the 2014 European Society of Cardiology Guideline on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (Evidence from HCM).Affairs of the heart: outcomes in men and women with hypertrophic cardiomyopathy.Long-term outcomes for different surgical strategies to treat left ventricular outflow tract obstruction in hypertrophic cardiomyopathy.Contemporary trends in cardiogenic shock: Incidence, intra-aortic balloon pump utilisation and outcomes from the London Heart Attack Group.The quest for perfection: the contribution of the electrocardiogram to the prevention of sudden death in hypertrophic cardiomyopathy.Prevalence and outcomes of coronary artery perforation during percutaneous coronary intervention.Complete Versus Culprit-Only Lesion Intervention in Patients With Acute Coronary SyndromesSudden Cardiac Death in Hypertrophic CardiomyopathyThe long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathyPrevalence of Desmosomal Protein Gene Mutations in Patients With Dilated CardiomyopathyOutcomes following the surgical management of left ventricular outflow tract obstruction; A systematic review and meta-analysisEffectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysisAngiography Alone Versus Angiography Plus Optical Coherence Tomography to Guide Percutaneous Coronary InterventionExercise-Induced Left Ventricular Outflow Tract Obstruction in Symptomatic Patients With Anderson-Fabry DiseaseCardiac involvement in Anderson-Fabry diseasePrevention of sudden cardiac death in hypertrophic cardiomyopathyCor triatriatum and hypertrophic cardiomyopathyCoronary artery dissection in the puerperium: A case report and literature reviewRoutine use of fluoroscopic guidance and up-front femoral angiography results in reduced femoral complications in patients undergoing coronary angiographic procedures: an observational study using an Interrupted Time-Series analysisComplete versus culprit only revascularisation in patients with cardiogenic shock complicating acute myocardial infarction: Incidence and outcomes from The London Heart Attack GroupDevelopment of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids)
P50
Q33162274-38163AC0-CD0E-4EC3-9693-66B2DF969AA9Q33163399-3F4C9F08-9638-4A70-88EC-376FA938E8AEQ34445272-2E48809D-2C2F-4102-9656-1682A2F9A08DQ36533003-35AB1D23-F0F8-4C9F-91B6-E026169CC63FQ37683034-657BB97B-CB04-47EF-A05A-A179E009743CQ38135337-5A2FE7CA-A700-4800-A371-E5A88ADCCA7EQ39042794-B964ACED-A3E9-4C96-8045-48D460C531E1Q39715709-15AEB4E5-C264-4E42-8AF7-EC85F5FAEFA0Q40503224-944D13AB-A8B4-452E-A911-184EC08B310FQ40505058-721DA4B3-819C-4DED-9D1D-CF713F6BA3BAQ46470790-AF8389DC-F61B-42C0-B852-BCA6DA5A24F1Q48259549-13E609C5-DD73-444F-88D0-815FD2E73CE3Q48307237-8AADB4A5-493F-4B6C-9B26-16E7D3C37DEAQ48546767-EBC8A516-7B6E-41ED-AFB9-B74989D10106Q49813639-C4854EF0-3299-487B-B4DA-D4786D6C8A61Q49932545-C8AE34EB-A0CF-4AD5-80C4-95B121EC8AB5Q50124638-A4DC7511-8499-4701-B1D5-E886F62F1D49Q51848513-1237A8FA-2EFB-46C9-9E64-C26242018E1EQ52679717-4C52F6CD-7292-41C2-A662-6D42CFAD6974Q57797489-7A6C0AC2-59C6-443D-835A-0C0EE0C03E67Q57901757-20414EB2-FC2C-402A-AC7D-4F83FDA9447AQ57901799-46BF25B5-29B6-488C-A16D-EE51AFACC1E3Q57901844-3E30B7A9-9BA8-4BD7-B789-3CE22B7B084EQ57929611-96EC1F3A-EECA-4EAE-B3AE-4F260A9DB733Q58114122-B05CADD1-12A6-4CB8-A3E9-9F28FBA14502Q61651151-ED67DCF6-87BE-45B2-AA16-7B13AE67E67CQ63363512-69192786-37D3-417A-BD74-238D23417C69Q64043153-6B27940D-5EE5-4592-BFDD-54A20A35E33BQ86573567-DC66B91D-8AF1-431B-BC2A-C30B1B443744Q87359922-2103D3DE-331F-4101-80E9-EB2F3B0E5838Q91438992-DA56D73A-8A26-423B-92FB-EBE19F0A5E41Q91837902-B41719F0-D653-442F-99EC-9C324ABE740AQ92056918-AF5CB9FE-153E-40CA-ACC3-0BBAFDAF21CAQ92614365-6EDE5157-CE3A-4250-9F44-149A562A0DE6
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
C O'Mahony
@en
C O'Mahony
@nl
type
label
C O'Mahony
@en
C O'Mahony
@nl
prefLabel
C O'Mahony
@en
C O'Mahony
@nl
P31
P496
0000-0001-6931-4647